Cargando…
Integrin Targeted Therapeutics
Integrins are heterodimeric, transmembrane receptors that function as mechanosensors, adhesion molecules and signal transduction platforms in a multitude of biological processes. As such, integrins are central to the etiology and pathology of many disease states. Therefore, pharmacological inhibitio...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086618/ https://www.ncbi.nlm.nih.gov/pubmed/21547158 |
_version_ | 1782202708356235264 |
---|---|
author | Millard, Melissa Odde, Srinivas Neamati, Nouri |
author_facet | Millard, Melissa Odde, Srinivas Neamati, Nouri |
author_sort | Millard, Melissa |
collection | PubMed |
description | Integrins are heterodimeric, transmembrane receptors that function as mechanosensors, adhesion molecules and signal transduction platforms in a multitude of biological processes. As such, integrins are central to the etiology and pathology of many disease states. Therefore, pharmacological inhibition of integrins is of great interest for the treatment and prevention of disease. In the last two decades several integrin-targeted drugs have made their way into clinical use, many others are in clinical trials and still more are showing promise as they advance through preclinical development. Herein, this review examines and evaluates the various drugs and compounds targeting integrins and the disease states in which they are implicated. |
format | Text |
id | pubmed-3086618 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-30866182011-05-05 Integrin Targeted Therapeutics Millard, Melissa Odde, Srinivas Neamati, Nouri Theranostics Review Integrins are heterodimeric, transmembrane receptors that function as mechanosensors, adhesion molecules and signal transduction platforms in a multitude of biological processes. As such, integrins are central to the etiology and pathology of many disease states. Therefore, pharmacological inhibition of integrins is of great interest for the treatment and prevention of disease. In the last two decades several integrin-targeted drugs have made their way into clinical use, many others are in clinical trials and still more are showing promise as they advance through preclinical development. Herein, this review examines and evaluates the various drugs and compounds targeting integrins and the disease states in which they are implicated. Ivyspring International Publisher 2011-02-17 /pmc/articles/PMC3086618/ /pubmed/21547158 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. |
spellingShingle | Review Millard, Melissa Odde, Srinivas Neamati, Nouri Integrin Targeted Therapeutics |
title | Integrin Targeted Therapeutics |
title_full | Integrin Targeted Therapeutics |
title_fullStr | Integrin Targeted Therapeutics |
title_full_unstemmed | Integrin Targeted Therapeutics |
title_short | Integrin Targeted Therapeutics |
title_sort | integrin targeted therapeutics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086618/ https://www.ncbi.nlm.nih.gov/pubmed/21547158 |
work_keys_str_mv | AT millardmelissa integrintargetedtherapeutics AT oddesrinivas integrintargetedtherapeutics AT neamatinouri integrintargetedtherapeutics |